My NCBISign In

Display Settings:

Format

Send to:

Choose Destination
    Mult Scler. 2012 Jan 17. [Epub ahead of print]

    Subcutaneous administration of alemtuzumab in patients with highly active multiple sclerosis.

    Perumal JS, Foo F, Cook P, Khan O.

    Source

    Department of Neurology, Weill Cornell Medical College, New York, USA.

    Abstract

    Alemtuzumab is an anti-CD52 monoclonal antibody with remarkable efficacy in relapsing multiple sclerosis (MS). In clinical trials and off-label use in MS, alemtuzumab has been administered intravenously (IV). Alemtuzumab is approved for chronic lymphoid leukemia as IV. Oncology guidelines recommend alemtuzumab subcutaneous (SC) over IV. There is no report of alemtuzumab SC in MS. We report two patients with highly active relapsing MS who were treated with SC alemtuzumab, had significant improvement and tolerated SC alemtuzumab well without the typical infusion-associated adverse events. SC alemtuzumab in MS warrants further studies as this may enhance patient convenience and minimize infusion-associated adverse events.

    PMID:
    22252465
    [PubMed - as supplied by publisher]

    LinkOut - more resources

    Full Text Sources

      Supplemental Content

      Icon for HighWire Press

      Save items

      loading

      Related citations in PubMed

      See reviews... See all...

      Recent activity

      Clear Turn Off Turn On

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      You are here: NCBI > Literature > PubMed
      Write to the Help Desk